FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Stock analysts at Brookline Cap M issued their FY2025 earnings per share estimates for shares of Cognition Therapeutics in a research report issued to clients and investors on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed anticipates that the company will earn ($0.35) per share for the year. Brookline Cap M currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Brookline Cap M also issued estimates for Cognition Therapeutics’ Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($0.46) EPS.

Several other research firms have also issued reports on CGTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, December 29th. Brookline Capital Acquisition raised shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Tuesday. B. Riley Financial reissued a “buy” rating and issued a $3.00 price objective (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday, November 21st. Wall Street Zen upgraded Cognition Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Cognition Therapeutics in a report on Thursday, December 4th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cognition Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $3.33.

Cognition Therapeutics Price Performance

Shares of NASDAQ CGTX traded up $0.06 during mid-day trading on Friday, hitting $1.06. 971,172 shares of the company’s stock traded hands, compared to its average volume of 992,105. The company’s 50-day moving average is $1.45 and its two-hundred day moving average is $1.56. The company has a market capitalization of $93.57 million, a P/E ratio of -2.21 and a beta of 1.25. Cognition Therapeutics has a 1 year low of $0.22 and a 1 year high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC lifted its position in shares of Cognition Therapeutics by 814.1% during the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock valued at $422,000 after buying an additional 897,353 shares during the last quarter. DAVENPORT & Co LLC bought a new position in shares of Cognition Therapeutics during the 3rd quarter worth approximately $3,631,000. CWA Asset Management Group LLC purchased a new stake in Cognition Therapeutics during the third quarter valued at approximately $34,000. McAdam LLC purchased a new stake in Cognition Therapeutics during the third quarter valued at approximately $97,000. Finally, Bryn Mawr Trust Advisors LLC grew its holdings in Cognition Therapeutics by 69.1% in the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock worth $53,000 after purchasing an additional 16,129 shares during the last quarter. 43.35% of the stock is owned by institutional investors.

Key Headlines Impacting Cognition Therapeutics

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CGTX to “Strong‑Buy” and released a set of quarterly and full‑year EPS estimates that are less negative than market consensus (Brookline FY2026: -$0.46 vs. consensus -$0.80). The upgrade plus narrower loss estimates likely improved investor expectations for future valuation and financing needs. Brookline coverage (MarketBeat)
• Positive Sentiment: Cognition extended the duration of its expanded access program (EAP) for Zervimesine (CT1812) in dementia with Lewy bodies, allowing enrolled patients additional months of treatment — a sign of ongoing clinical engagement and potential real‑world data generation that can de‑risk the program incrementally. GlobeNewswire: EAP extension
• Neutral Sentiment: Multiple Brookline research notes repeated the same forward‑looking quarterly estimates (Q4‑2025 through Q4‑2026) and the Strong‑Buy call — the breadth of published estimates helps set expectations but adds little new detail beyond the upgrade. Brookline coverage (MarketBeat)
• Negative Sentiment: Despite the more favorable forecasts from Brookline, Cognition remains a clinical‑stage company with no approved products and ongoing projected losses (consensus FY current year ~ -$0.80 EPS). That keeps the stock exposed to clinical, regulatory and financing risk, which can drive volatility and dilution. Market context (MarketBeat)

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.